GSA Capital Partners LLP Invests $121,000 in Shattuck Labs, Inc. (NASDAQ:STTK)

GSA Capital Partners LLP purchased a new stake in Shattuck Labs, Inc. (NASDAQ:STTK) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 34,699 shares of the company’s stock, valued at approximately $121,000. GSA Capital Partners LLP owned about 0.07% of Shattuck Labs at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of STTK. Bank of New York Mellon Corp increased its position in Shattuck Labs by 209.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 222,034 shares of the company’s stock worth $857,000 after purchasing an additional 150,340 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Shattuck Labs by 38.2% in the first quarter. Vanguard Group Inc. now owns 1,819,926 shares of the company’s stock valued at $16,270,000 after buying an additional 502,860 shares during the last quarter. Virtu Financial LLC acquired a new stake in Shattuck Labs during the first quarter worth approximately $113,000. American Century Companies Inc. grew its stake in Shattuck Labs by 25.4% in the 2nd quarter. American Century Companies Inc. now owns 47,367 shares of the company’s stock worth $183,000 after acquiring an additional 9,608 shares during the period. Finally, Acadian Asset Management LLC acquired a new position in Shattuck Labs in the 2nd quarter valued at $170,000. Institutional investors and hedge funds own 58.74% of the company’s stock.

Insiders Place Their Bets

In related news, CEO Taylor Schreiber acquired 36,500 shares of the stock in a transaction dated Monday, October 7th. The shares were acquired at an average price of $1.21 per share, for a total transaction of $44,165.00. Following the completion of the purchase, the chief executive officer now owns 71,002 shares in the company, valued at approximately $85,912.42. The trade was a 105.79 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 10.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on STTK. Needham & Company LLC reissued a “hold” rating on shares of Shattuck Labs in a research report on Thursday, November 14th. Evercore ISI upgraded Shattuck Labs to a “strong-buy” rating in a research report on Wednesday, October 2nd. Citigroup lowered shares of Shattuck Labs from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $8.00 to $2.00 in a research report on Wednesday, October 2nd. Finally, HC Wainwright reaffirmed a “neutral” rating on shares of Shattuck Labs in a research note on Friday, November 15th. Four equities research analysts have rated the stock with a hold rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Shattuck Labs has an average rating of “Hold” and an average price target of $8.67.

Shattuck Labs Trading Up 0.5 %

Shares of NASDAQ STTK opened at $1.01 on Tuesday. Shattuck Labs, Inc. has a one year low of $0.94 and a one year high of $11.76. The firm has a market capitalization of $48.22 million, a PE ratio of -0.66 and a beta of 1.85. The business has a 50-day moving average price of $1.76 and a two-hundred day moving average price of $3.77.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.